# Aclid

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aclid

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.aclid.bio
- Total disclosed funding: $3.6M
- Latest round: Seed (Jun 6, 2023)
- Investors on record: 2

## About

Founded in 2021 by its CEO, Kevin Flyangolts, and based in New York, US, Aclid, Inc., operates a biotechnology platform that provides various gene synthesis compliance solutions for customer verification, screening of DNA and RNA. In October 2023, new investors 2048 Ventures and IA Ventures co-led a USD 3.3 million in seed funding for Aclid, Inc.

Aclid offers a biosecurity platform used to provide threat assessments and risk profiles for extensive sequences of hundreds of thousands of base pairs to decrease risk factors and enhance biosecurity.

The platform automates the verification of licenses, registrations, adherence to biosafety guidelines, and legitimate usage.

The company plans to use the October 2023 funding to enable real-time screening demands.

## Funding rounds

- Seed, Jun 6, 2023, $3.6M — IA Ventures, 2048 Ventures

## Investors

- IA Ventures (https://capitalatlas.ai/funds/ia-ventures) — Seed
- 2048 Ventures (https://capitalatlas.ai/funds/2048-ventures) — Seed